ClinicalTrials.gg
CompletedNCT00373685GI-REASONSUpdated Mar 3, 2021Results posted

GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS)

A Phase 4 interventional study of Celecoxib and Any commercially available NSAID with the indication for osteoarthritis in Osteoarthritis, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 777 sites in 2 countries. Open to participants aged 55 Years to 99 Years. Per ClinicalTrials.gov, last updated 2021-03-03.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
8,067
Allocation
Randomized
Ages
55 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing celecoxib in Osteoarthritis — 1 open to participants now, 1 under way, none of them phase 3. Celecoxib · Osteoarthritis.

Enrollment
Largest of 14
8,067 · median 150
Started
2006
with 2 others
Phase 4
10 of 14
1 open now
Registered
7th of 14
by date
Lead sponsor
4 of 14
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 14 studies testing celecoxib in Osteoarthritis, this one has the largest enrollment, is one of 3 that started in 2006, is one of 10 in phase 4, and was the 7th registered.

Osteoarthritis

2,975 studies on the registry are indexed under Osteoarthritis; 436 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

1 of the 14 studies testing celecoxib in Osteoarthritis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About celecoxib

Celecoxib: first FDA approval 1998 (CELEBREX), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.

This study: 55 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing celecoxib in Osteoarthritis, or all of them as a file.
02

Study summary

This study investigates if Celebrex has a lower incident of Gastrointestinal Events than other NSAIDS in subjects with osteoarthritis.

03

Conditions studied

  • Osteoarthritis

Browse trials for

Keywords

  • GI events in patients with moderate GI risk treated with NSAIDS
04

Who can participate

Ages eligible
55 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients of at least 55 years of age with a clinical diagnosis of OA who are expected to require daily prescription anti-inflammatory analgesic therapy for arthritis symptom management and for whom either celecoxib or a nsNSAID is an appropriate treatment option.

Exclusion criteria

Exclusion Criteria:

  • GI ulcer hemorrhage or active GD ulceration less than 90 days prior to screening visit.
  • Patients with a history of myocardial infarction, unstable angina, ischemic or hemorrhagic stroke, , previous revascularization procedure to coronary, carotid, cerebral, renal, aortic or peripheral arterial vasculature.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
8,067 participants (actual)

Study arms

  • Experimental
    Celecoxib

    dosing as per USPI label

    Drug: Celecoxib

  • Active comparator
    NSAIDs

    Drug: Any commercially available NSAID with the indication for osteoarthritis

Interventions

  • open-label

  • DrugAny commercially available NSAID with the indication for osteoarthritis

    dosing as per USPI label related to the chosen commercially marketed NSAID

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Clinically Significant Upper and/or Lower Gastrointestinal Events (CSULGIEs)

    CSULGIE defined as any of the following: gastroduodenal (GD) hemorrhage; gastric outlet obstruction; GD, small or large bowel perforation; small or large bowel hemorrhage; acute gastrointestinal (GI) hemorrhage of unknown origin; small bowel obstruction; clinically significant anemia/blood loss of defined GI origin or presumed occult GI origin.

    Time frame: Baseline through week 24 or Early Termination (ET)

Secondary outcomes

  1. Percentage of Participants With Moderate to Severe Abdominal Symptoms

    Abdominal symptoms coded using the Medical Dictionary for Regulatory Activities (MedDRA) System Organ Class (SOC) 'Gastrointestinal Disorders' high level group term (HLGT) equal to "Gastrointestinal Signs and Symptoms"; where moderate indicated the gastrointestinal adverse event (GI AE) interfered to some extent with the participants' usual function and severe indicated the GI AE interfered significantly with participants' usual function.

    Time frame: Baseline through week 24 or ET

  2. Percentage of Participants Who Withdrew Due to GI Adverse Events (AEs)

    GI AEs defined using MedDRA SOC 'Gastrointestinal Disorders' but excluding HLGT's: Benign Neoplasms Gastrointestinal, Dental and Gingival Conditions, Oral Soft Tissue Conditions, Salivary Gland Conditions and Tongue Conditions

    Time frame: Baseline through week 24 or ET

  3. Hemoglobin (Hb) at Baseline

    Time frame: Baseline

  4. Change From Baseline Hb at Week 24

    Time frame: Baseline and Week 24 or ET

  5. Hematocrit (Hct) at Baseline

    Time frame: Baseline

  6. Change From Baseline Hct at Week 24

    Time frame: Baseline and Week 24 or ET

  7. Percentage of Participants With Clinically Significant Decrease in Hct and/or Hb From Baseline

    Clinically significant decrease in Hct (greater than or equal to 10 percent \[≥10%\]) and/or decrease in Hb (≥ 2 g/dL).

    Time frame: Baseline, Weeks 8, 16, 24 or ET

  8. Percentage of Participants Satisfied With Efficacy of Current Pain Medication Overall

    Percentage of participants who reported Very Satisfied or Satisfied with current pain medication question on the Patient Treatment Satisfaction Scale (PTSS), scale ranged from Very Satisfied (1) to Very Dissatisfied (5).

    Time frame: Baseline, Weeks 8, 16, 24 or ET

  9. Percentage of Participants Satisfied With Efficacy of Current Pain Medication - Time to Pain Relief

    Percentage of participants who reported Very Satisfied or Satisfied with efficacy of current pain medication questions on the PTSS Efficacy subscale for the time it took medication to work, scale ranged from Very Satisfied (1) to Very Dissatisfied (5). Possible range of scores 1 to 15.

    Time frame: Baseline, Weeks 8, 16, 24 or ET

  10. Percentage of Participants Satisfied With Efficacy of Current Pain Medication - Amount of Pain Relief

    Percentage of participants who reported Very Satisfied or Satisfied with efficacy of current pain medication questions on the PTSS Efficacy subscale for the amount of pain relief medication provided, scale ranged from Very Satisfied (1) to Very Dissatisfied (5). Possible range of scores 1 to 15.

    Time frame: Baseline, Weeks 8, 16, 24 or ET

  11. Percentage of Participants Satisfied With Efficacy of Current Pain Medication - Duration of Pain Relief

    Percentage of participants who reported Very Satisfied or Satisfied with efficacy of current pain medication questions on the PTSS Efficacy, subscale for duration of pain relief provided by medication, scale ranged from Very Satisfied (1) to Very Dissatisfied (5). Possible range of scores 1 to 15.

    Time frame: Baseline, Weeks 8, 16, 24 or ET

Other outcomes

  1. Percentage of Participants With Positive Blood Fecal Occult

    Positive blood fecal occult; blood in feces that is not visibly apparent

    Time frame: Week 24 or ET

  2. Percentage of Participants With Proton Pump Inhibitor (PPI) and Other Gastric Protective Drug Utilization

    PPI and other gastric protective drug (defined as Histamine-2 receptor antagonists \[H2RA\], misoprostol, sucralfate, and others such as antacids) utilization.

    Time frame: Baseline through week 24 or ET

  3. Percentage of Participants With Non-study Medication Utilization

    Non-study medication utilization associated with initial treatment defined as narcotic analgesics and acetaminophen use.

    Time frame: Baseline through week 24 or ET

07

Results

Posted Nov 30, 2011

Participant flow

Participant flow — Overall Study
MilestoneCelecoxibnsNSAIDs
Started40354032
Treated39843955
Completed25962611
Not completed14391421
Withdrew: Death21
Withdrew: Adverse event278253
Withdrew: Insufficient clinical response169119
Withdrew: Did not meet entrance criteria167184
Withdrew: Lost to follow up83103
Withdrew: No longer willing to participate337352
Withdrew: Other149146
Withdrew: Protocol violation191182
Withdrew: Final status unknown124
Withdrew: Randomized, not treated5177

Outcome measures

PrimaryPercentage of Participants With Clinically Significant Upper and/or Lower Gastrointestinal Events (CSULGIEs)

CSULGIE defined as any of the following: gastroduodenal (GD) hemorrhage; gastric outlet obstruction; GD, small or large bowel perforation; small or large bowel hemorrhage; acute gastrointestinal (GI) hemorrhage of unknown origin; small bowel obstruction; clinically significant anemia/blood loss of defined GI origin or presumed occult GI origin.

Time frame:
Baseline through week 24 or Early Termination (ET)
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinically Significant Upper and/or Lower Gastrointestinal Events (CSULGIEs)
Percentage of participantsCelecoxibnsNSAIDs
Percentage of Participants With Clinically Significant Upper and/or Lower Gastrointestinal Events (CSULGIEs)1.32.4
Statistical analysis
  • Celecoxib vs nsNSAIDs · Life Table Extension of CMH Test · p = 0.0003 (Life Table Extension of Cochran-Mantel-Haenszel (CMH) Test)
SecondaryPercentage of Participants With Moderate to Severe Abdominal Symptoms

Abdominal symptoms coded using the Medical Dictionary for Regulatory Activities (MedDRA) System Organ Class (SOC) 'Gastrointestinal Disorders' high level group term (HLGT) equal to "Gastrointestinal Signs and Symptoms"; where moderate indicated the gastrointestinal adverse event (GI AE) interfered to some extent with the participants' usual function and severe indicated the GI AE interfered significantly with participants' usual function.

Time frame:
Baseline through week 24 or ET
Reported as:
Number · Percentage of participants
Percentage of Participants With Moderate to Severe Abdominal Symptoms
Percentage of participantsCelecoxibnsNSAIDs
Percentage of Participants With Moderate to Severe Abdominal Symptoms2.33.4
Statistical analysis
  • Celecoxib vs nsNSAIDs · Life Table Extension of CMH Test · p = 0.0035
SecondaryPercentage of Participants Who Withdrew Due to GI Adverse Events (AEs)

GI AEs defined using MedDRA SOC 'Gastrointestinal Disorders' but excluding HLGT's: Benign Neoplasms Gastrointestinal, Dental and Gingival Conditions, Oral Soft Tissue Conditions, Salivary Gland Conditions and Tongue Conditions

Time frame:
Baseline through week 24 or ET
Reported as:
Number · Percentage of participants
Percentage of Participants Who Withdrew Due to GI Adverse Events (AEs)
Percentage of participantsCelecoxibnsNSAIDs
Percentage of Participants Who Withdrew Due to GI Adverse Events (AEs)2.83.0
Statistical analysis
  • Celecoxib vs nsNSAIDs · Life Table Extension of CMH Test · p = 0.6140
SecondaryHemoglobin (Hb) at Baseline
Time frame:
Baseline
Reported as:
Mean · gram per deciliter (g/dL)
Hemoglobin (Hb) at Baseline
gram per deciliter (g/dL)CelecoxibnsNSAIDs
Hemoglobin (Hb) at Baseline13.6 ± 1.113.6 ± 1.2
SecondaryChange From Baseline Hb at Week 24
Time frame:
Baseline and Week 24 or ET
Reported as:
Least squares mean · g/dL
Change From Baseline Hb at Week 24
g/dLCelecoxibnsNSAIDs
Change From Baseline Hb at Week 24-0.109 ± 0.012-0.241 ± 0.012
Statistical analysis
  • Celecoxib vs nsNSAIDs · ANCOVA · p = <0.0001 (P-value associated with Overall (LOCF))
SecondaryHematocrit (Hct) at Baseline
Time frame:
Baseline
Reported as:
Mean · Percent
Hematocrit (Hct) at Baseline
PercentCelecoxibnsNSAIDs
Hematocrit (Hct) at Baseline40.8 ± 3.440.9 ± 3.4
SecondaryChange From Baseline Hct at Week 24
Time frame:
Baseline and Week 24 or ET
Reported as:
Least squares mean · Percent
Change From Baseline Hct at Week 24
PercentCelecoxibnsNSAIDs
Change From Baseline Hct at Week 24-0.330 ± 0.038-0.716 ± 0.039
Statistical analysis
  • Celecoxib vs nsNSAIDs · ANCOVA · p = <0.0001 (P-value associated with Overall (LOCF))
SecondaryPercentage of Participants With Clinically Significant Decrease in Hct and/or Hb From Baseline

Clinically significant decrease in Hct (greater than or equal to 10 percent \[≥10%\]) and/or decrease in Hb (≥ 2 g/dL).

Time frame:
Baseline, Weeks 8, 16, 24 or ET
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinically Significant Decrease in Hct and/or Hb From Baseline
Percentage of participantsCelecoxibnsNSAIDs
Week 8 (n= 3043, 3086)0.70.9
Week 16 (n=2687, 2675)0.81.6
Week 24 (n=3278, 3207)0.91.5
Week 24 LOCF (n=3604, 3574)1.82.9
Statistical analysis
  • Celecoxib vs nsNSAIDs · Cochran-Mantel-Haenszel · p = 0.0023 (P-value associated with Overall (LOCF))
SecondaryPercentage of Participants Satisfied With Efficacy of Current Pain Medication Overall

Percentage of participants who reported Very Satisfied or Satisfied with current pain medication question on the Patient Treatment Satisfaction Scale (PTSS), scale ranged from Very Satisfied (1) to Very Dissatisfied (5).

Time frame:
Baseline, Weeks 8, 16, 24 or ET
Reported as:
Number · Percentage of participants
Percentage of Participants Satisfied With Efficacy of Current Pain Medication Overall
Percentage of participantsCelecoxibnsNSAIDs
Baseline (n=3887, 3904)39.838.0
Week 8 (n=3181, 3199)78.569.5
Week 16 (n=2784, 2772)81.974.6
Week 24 or ET (n=3383, 3361)74.670.8
Week 24/LOCF (n=3672, 3651)74.570.3
Statistical analysis
  • Celecoxib vs nsNSAIDs · Chi-squared · p = 0.1008
  • Celecoxib vs nsNSAIDs · Chi-squared · p = <0.0001
  • Celecoxib vs nsNSAIDs · Chi-squared · p = <0.0001
  • Celecoxib vs nsNSAIDs · Chi-squared · p = 0.0005
  • Celecoxib vs nsNSAIDs · Chi-squared · p = <0.0001
SecondaryPercentage of Participants Satisfied With Efficacy of Current Pain Medication - Time to Pain Relief

Percentage of participants who reported Very Satisfied or Satisfied with efficacy of current pain medication questions on the PTSS Efficacy subscale for the time it took medication to work, scale ranged from Very Satisfied (1) to Very Dissatisfied (5). Possible range of scores 1 to 15.

Time frame:
Baseline, Weeks 8, 16, 24 or ET
Reported as:
Number · Percentage of participants
Percentage of Participants Satisfied With Efficacy of Current Pain Medication - Time to Pain Relief
Percentage of participantsCelecoxibnsNSAIDs
Baseline (n=3890, 3905)43.243.7
Week 8 (n=3185, 3202)80.271.6
Week 16 (n=2784,2777)83.277.7
Week 24 or ET (n=3386,3362)76.273.8
Week 24/LOCF (n=3672, 3653)76.073.3
Statistical analysis
  • Celecoxib vs nsNSAIDs · Chi-squared · p = 0.6562
  • Celecoxib vs nsNSAIDs · Chi-squared · p = <0.0001
  • Celecoxib vs nsNSAIDs · Chi-squared · p = <0.0001
  • Celecoxib vs nsNSAIDs · Chi-squared · p = 0.0245
  • Celecoxib vs nsNSAIDs · Chi-squared · p = 0.0074
SecondaryPercentage of Participants Satisfied With Efficacy of Current Pain Medication - Amount of Pain Relief

Percentage of participants who reported Very Satisfied or Satisfied with efficacy of current pain medication questions on the PTSS Efficacy subscale for the amount of pain relief medication provided, scale ranged from Very Satisfied (1) to Very Dissatisfied (5). Possible range of scores 1 to 15.

Time frame:
Baseline, Weeks 8, 16, 24 or ET
Reported as:
Number · Percentage of participants
Percentage of Participants Satisfied With Efficacy of Current Pain Medication - Amount of Pain Relief
Percentage of participantsCelecoxibnsNSAIDs
Baseline (n=3888, 3905)41.440.5
Week 8 (n=3185, 3203)77.469.2
Week 16 (n=2783, 2778)80.574.5
Week 24 or ET (n=3385, 3362)74.071.3
Week 24/LOCF (n=3671, 3653)74.070.8
Statistical analysis
  • Celecoxib vs nsNSAIDs · Chi-squared · p = 0.4074
  • Celecoxib vs nsNSAIDs · Chi-squared · p = <0.0001
  • Celecoxib vs nsNSAIDs · Chi-squared · p = <0.0001
  • Celecoxib vs nsNSAIDs · Chi-squared · p = 0.0127
  • Celecoxib vs nsNSAIDs · Chi-squared · p = 0.0019
SecondaryPercentage of Participants Satisfied With Efficacy of Current Pain Medication - Duration of Pain Relief

Percentage of participants who reported Very Satisfied or Satisfied with efficacy of current pain medication questions on the PTSS Efficacy, subscale for duration of pain relief provided by medication, scale ranged from Very Satisfied (1) to Very Dissatisfied (5). Possible range of scores 1 to 15.

Time frame:
Baseline, Weeks 8, 16, 24 or ET
Reported as:
Number · Percentage of participants
Percentage of Participants Satisfied With Efficacy of Current Pain Medication - Duration of Pain Relief
Percentage of participantsCelecoxibnsNSAIDs
Baseline (n=3886, 3905)37.836.6
Week 8 (n=3182, 3202)75.466.8
Week 16 (n=2780,2778)77.871.6
Week 24 or ET (n=3383,3361)72.268.8
Week 24/LOCF (n=3671, 3653)72.268.2
Statistical analysis
  • Celecoxib vs nsNSAIDs · Chi-squared · p = 0.2699
  • Celecoxib vs nsNSAIDs · Chi-squared · p = <0.0001
  • Celecoxib vs nsNSAIDs · Chi-squared · p = <0.0001
  • Celecoxib vs nsNSAIDs · Chi-squared · p = 0.0027
  • Celecoxib vs nsNSAIDs · Chi-squared · p = 0.0001
Other pre-specifiedPercentage of Participants With Positive Blood Fecal Occult

Positive blood fecal occult; blood in feces that is not visibly apparent

Time frame:
Week 24 or ET
Reported as:
Number · Percentage of participants
Percentage of Participants With Positive Blood Fecal Occult
Percentage of participantsCelecoxibnsNSAIDs
Percentage of Participants With Positive Blood Fecal Occult1.11.4
Other pre-specifiedPercentage of Participants With Proton Pump Inhibitor (PPI) and Other Gastric Protective Drug Utilization

PPI and other gastric protective drug (defined as Histamine-2 receptor antagonists \[H2RA\], misoprostol, sucralfate, and others such as antacids) utilization.

Time frame:
Baseline through week 24 or ET
Reported as:
Number · Percentage of participants
Percentage of Participants With Proton Pump Inhibitor (PPI) and Other Gastric Protective Drug Utilization
Percentage of participantsCelecoxibnsNSAIDs
PPIs23.024.2
H2RAs5.05.7
Gastric protective agents0.91.0
Other pre-specifiedPercentage of Participants With Non-study Medication Utilization

Non-study medication utilization associated with initial treatment defined as narcotic analgesics and acetaminophen use.

Time frame:
Baseline through week 24 or ET
Reported as:
Number · Percentage of participants
Percentage of Participants With Non-study Medication Utilization
Percentage of participantsCelecoxibnsNSAIDs
Acetaminophen6.86.5
Acetylsalicylic acid (ASA)3.53.0
NSAIDs12.813.3
Opioids14.215.6

Adverse events

Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Celecoxib—99/3,970 (2.5%)962/3,970 (24.2%)
nsNSAIDs—95/3,951 (2.4%)1,163/3,951 (29.4%)
Most frequent serious events
Showing 10 of 160
Most frequent serious events
EventCelecoxibnsNSAIDs
Chest painGeneral disorders10/39707/3951
OsteoarthritisMusculoskeletal and connective tissue disorders9/39703/3951
PneumoniaInfections and infestations5/39703/3951
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders5/39702/3951
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)4/39702/3951
Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)4/39701/3951
AppendicitisInfections and infestations0/39703/3951
DiverticulitisInfections and infestations3/39703/3951
Back painMusculoskeletal and connective tissue disorders1/39703/3951
ParaesthesiaNervous system disorders0/39703/3951
Most frequent other events
Showing 10 of 25
Most frequent other events
EventCelecoxibnsNSAIDs
DiarrhoeaGastrointestinal disorders84/3970115/3951
NauseaGastrointestinal disorders65/3970112/3951
Upper respiratory tract infectionInfections and infestations112/397075/3951
DyspepsiaGastrointestinal disorders65/397098/3951
SinusitisInfections and infestations75/397088/3951
BronchitisInfections and infestations86/397077/3951
Haemoglobin decreasedInvestigations59/397084/3951
HeadacheNervous system disorders67/397083/3951
ArthralgiaMusculoskeletal and connective tissue disorders82/397073/3951
Gastrooesophageal reflux diseaseGastrointestinal disorders29/397078/3951

Baseline characteristics

Age, Customized
Age, Customized(Participants)CelecoxibnsNSAIDsTotal
<55 years527
55-59 years133913612700
60-64 years114911272276
65-69 years8488221670
70-74 years5045171021
>=75 years184197381
Unspecified6612
Sex/Gender, Customized
Sex/Gender, Customized(Participants)CelecoxibnsNSAIDsTotal
Male9809621942
Female304930646113
Unspecified6612
08

Study locations

777 sites
  • Pfizer Investigational Site
    Abbeville, Alabama 36310, United States
  • Pfizer Investigational Site
    Alexander City, Alabama 35010, United States
  • Pfizer Investigational Site
    Bay Minette, Alabama 36507-4185, United States
  • Pfizer Investigational Site
    Birmingham, Alabama 35205, United States
  • Pfizer Investigational Site
    Birmingham, Alabama 35209, United States
  • Pfizer Investigational Site
    Birmingham, Alabama 35215, United States
  • Pfizer Investigational Site
    Birmingham, Alabama 35218, United States
  • Pfizer Investigational Site
    Birmingham, Alabama 35235, United States
  • Pfizer Investigational Site
    Birmingham, Alabama 35244, United States
  • Pfizer Investigational Site
    Cullman, Alabama 35058, United States
  • Pfizer Investigational Site
    Dothan, Alabama 36301, United States
  • Pfizer Investigational Site
    Dothan, Alabama 36303, United States
  • Pfizer Investigational Site
    Geneva, Alabama 36340, United States
  • Pfizer Investigational Site
    Gulf Shores, Alabama 36547, United States
  • Pfizer Investigational Site
    Guntersville, Alabama 35976, United States
  • Pfizer Investigational Site
    Huntsville, Alabama 35801, United States
  • Pfizer Investigational Site
    Huntsville, Alabama 35824, United States
  • Pfizer Investigational Site
    Jacksonville, Alabama 36265, United States
  • Pfizer Investigational Site
    Mobile, Alabama 36604-1416, United States
  • Pfizer Investigational Site
    Montgomery, Alabama 36106, United States
  • Pfizer Investigational Site
    Muscle Shoals, Alabama 35662, United States
  • Pfizer Investigational Site
    Ozark, Alabama 36360, United States
  • Pfizer Investigational Site
    Pell City, Alabama 32515, United States
  • Pfizer Investigational Site
    Tallassee, Alabama 36078, United States
  • Pfizer Investigational Site
    Chandler, Arizona 85224, United States
  • Pfizer Investigational Site
    Glendale, Arizona 85308, United States
  • Pfizer Investigational Site
    Green Valley, Arizona 85614, United States
  • Pfizer Investigational Site
    Mesa, Arizona 85203, United States
  • Pfizer Investigational Site
    Mesa, Arizona 85206, United States
  • Pfizer Investigational Site
    Phoenix, Arizona 85016, United States
  • Pfizer Investigational Site
    Phoenix, Arizona 85023, United States
  • Pfizer Investigational Site
    Phoenix, Arizona 85028, United States
  • Pfizer Investigational Site
    Phoenix, Arizona 85032, United States
  • Pfizer Investigational Site
    Phoenix, Arizona 85051, United States
  • Pfizer Investigational Site
    Scottsdale, Arizona 85258, United States
  • Pfizer Investigational Site
    Sierra Vista, Arizona 85635, United States
  • Pfizer Investigational Site
    Sun Lakes, Arizona 85248, United States
  • Pfizer Investigational Site
    Tempe, Arizona 85282, United States
  • Pfizer Investigational Site
    Tempe, Arizona 85283, United States
  • Pfizer Investigational Site
    Tucson, Arizona 85712, United States
  • Pfizer Investigational Site
    Tucson, Arizona 85719, United States
  • Pfizer Investigational Site
    Hot Springs, Arkansas 71913, United States
  • Pfizer Investigational Site
    Little Rock, Arkansas 72205, United States
  • Pfizer Investigational Site
    Paragould, Arkansas 72450, United States
  • Pfizer Investigational Site
    Pine Bluff, Arkansas 71603, United States
  • Pfizer Investigational Site
    Anaheim, California 92801, United States
  • Pfizer Investigational Site
    Anaheim, California 92804, United States
  • Pfizer Investigational Site
    Bakersfield, California 93309, United States
  • Pfizer Investigational Site
    Bellflower, California 90706, United States
  • Pfizer Investigational Site
    Bermuda Dunes, California 92203, United States
  • Pfizer Investigational Site
    Buena Park, California 90620-3886, United States
  • Pfizer Investigational Site
    Buena Park, California 90620, United States
  • Pfizer Investigational Site
    Carson, California 90745, United States
  • Pfizer Investigational Site
    Cerritos, California 90703, United States
  • Pfizer Investigational Site
    Chula Vista, California 91910, United States
  • Pfizer Investigational Site
    Cudahy, California 90201, United States
  • Pfizer Investigational Site
    El Cajon, California 92019, United States
  • Pfizer Investigational Site
    El Segundo, California 90245, United States
  • Pfizer Investigational Site
    Encino, California 91436, United States
  • Pfizer Investigational Site
    Escondido, California 92025-3406, United States
  • Pfizer Investigational Site
    Fortuna, California 95540, United States
  • Pfizer Investigational Site
    Fremont, California 94536, United States
  • Pfizer Investigational Site
    Fresno, California 93710, United States
  • Pfizer Investigational Site
    Fresno, California 93726, United States
  • Pfizer Investigational Site
    Garden Grove, California 92843, United States
  • Pfizer Investigational Site
    Garden Grove, California 92845, United States
  • Pfizer Investigational Site
    Greenbrae, California 94904, United States
  • Pfizer Investigational Site
    Harbor City, California 90710, United States
  • Pfizer Investigational Site
    Hemet, California 92543, United States
  • Pfizer Investigational Site
    Huntington Beach, California 92646, United States
  • Pfizer Investigational Site
    Huntington Park, California 90255, United States
  • Pfizer Investigational Site
    Irvine, California 92618, United States
  • Pfizer Investigational Site
    La Jolla, California 92037-1233, United States
  • Pfizer Investigational Site
    La Palma, California 90623, United States
  • Pfizer Investigational Site
    Long Beach, California 90806, United States
  • Pfizer Investigational Site
    Long Beach, California 90807, United States
  • Pfizer Investigational Site
    Long Beach, California 90813, United States
  • Pfizer Investigational Site
    Los Angeles, California 90017, United States
  • Pfizer Investigational Site
    Los Angeles, California 90025, United States
  • Pfizer Investigational Site
    Los Angeles, California 90026, United States
  • Pfizer Investigational Site
    Los Angeles, California 90041-2321, United States
  • Pfizer Investigational Site
    Los Banos, California 93635, United States
  • Pfizer Investigational Site
    Los Gatos, California 95032, United States
  • Pfizer Investigational Site
    Marina Del Rey, California 90292-5425, United States
  • Pfizer Investigational Site
    Merced, California 95340, United States
  • Pfizer Investigational Site
    Mission Viejo, California 92691, United States
  • Pfizer Investigational Site
    Montebello, California 90640, United States
  • Pfizer Investigational Site
    Monterey Park, California 91754, United States
  • Pfizer Investigational Site
    Newport Beach, California 92260, United States
  • Pfizer Investigational Site
    Newport Beach, California 92660, United States
  • Pfizer Investigational Site
    Paramount, California 90723, United States
  • Pfizer Investigational Site
    Pismo Beach, California 93449, United States
  • Pfizer Investigational Site
    Rancho Cucamonga, California 91730, United States
  • Pfizer Investigational Site
    Redlands, California 92374, United States
  • Pfizer Investigational Site
    Reseda, California 91335, United States
  • Pfizer Investigational Site
    Rialto, California 92376, United States
  • Pfizer Investigational Site
    Riverside, California 92506, United States
  • Pfizer Investigational Site
    Rowland Heights, California 91748, United States
  • Pfizer Investigational Site
    Sacramento, California 95823, United States
  • Pfizer Investigational Site
    San Diego, California 92101, United States

Showing the first 100 of 777 sites across 2 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Cryer B, Li C, Simon LS, Singh G, Stillman MJ, Berger MF. GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trial. Am J Gastroenterol. 2013 Mar;108(3):392-400. doi: 10.1038/ajg.2012.467. Epub 2013 Feb 12. PubMed 23399552 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2006, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2011, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2006
First posted
Sep 8, 2006
Start
Oct 2006
Primary completionActual
Nov 2010
CompletionActual
Nov 2010
Results first posted
Nov 30, 2011
Last update
Mar 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00373685
Responsible party
Sponsor
First posted
Sep 8, 2006
Start date
Oct 2006
Primary completion
Nov 2010
Completion
Nov 2010
Results posted
Nov 30, 2011
Last update
Mar 3, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Celecoxib

Start the discussion